4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Purity >98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory

Short Description:

Name: 4-Chloro-7-Methoxyquinoline-6-Carboxamide

CAS: 417721-36-9

Purity: >98.5% (HPLC)

Appearance: Off-White to Light Yellow Powder

Intermediate of Lenvatinib Mesylate CAS 857890-39-2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib; 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4

Chemical Properties:

Chemical Name	4-Chloro-7-Methoxyquinoline-6-Carboxamide
Synonyms	4-Chloro-7-Methoxy-6-Quinolinecarboxamide; Lenvatinib Impurity 12; Lenvatinib Impurity B; Lenvatinib Impurity LFS-B
CAS Number	417721-36-9
CAT Number	RF-PI1971
Stock Status	In Stock, Production Capacity 50MT/Year
Molecular Formula	C11H9ClN2O2
Molecular Weight	236.65
Melting Point	>205℃ (dec.)
Density	1.380±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Off-White to Light Yellow Powder
Purity / Analysis Method	>98.5% (HPLC)
Loss on Drying	<0.50%
Residue on Ignition	<0.50%
Total Impurities	<1.50%
Proton NMR Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) is mainly used as an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Developed by Eisai Inc., lenvatinib mesylate is a vascular endothelial growth factor receptor (VEGF) inhibitor which has activity against VEGF subtypes 1, 2, and 3 and was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.